menu
    • menu
    [{"orgOrder":0,"company":"University of Minnesota","sponsor":"F. Hoffmann-La Roche | Pfizer Inc | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"University of Minnesota","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Minnesota \/ F. Hoffmann-La Roche | Pfizer Inc | Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"University of Minnesota \/ F. Hoffmann-La Roche | Pfizer Inc | Sanofi"},{"orgOrder":0,"company":"CytoAgents","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CTO1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CytoAgents \/ Undisclosed"},{"orgOrder":0,"company":"CytoAgents","sponsor":"TFS Health Science","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CTO1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ TFS Health Science","highestDevelopmentStatusID":"7","companyTruncated":"CytoAgents \/ TFS Health Science"},{"orgOrder":0,"company":"CytoAgents","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CTO1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CytoAgents \/ Undisclosed"},{"orgOrder":0,"company":"CytoAgents","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CTO1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CytoAgents \/ Undisclosed"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"CytoAgents","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"GP1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quotient Sciences \/ CytoAgents","highestDevelopmentStatusID":"7","companyTruncated":"Quotient Sciences \/ CytoAgents"},{"orgOrder":0,"company":"Leiden University","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"Leiden University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Leiden University \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Leiden University \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"University of Saskatchewan","sponsor":"University of Chicago | University of Calgary | University of Alberta | Gabrail Cancer Center Research | Wagner College, Staten Island, NY, USA | `Applied Speciation and Consulting LLC","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2015","type":"Inapplicable","leadProduct":"Anhydrous Selenite","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"University of Saskatchewan","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Saskatchewan \/ University of Chicago | University of Calgary | University of Alberta | Gabrail Cancer Center Research | Wagner College, Staten Island, NY, USA | `Applied Speciation and Consulting LLC","highestDevelopmentStatusID":"7","companyTruncated":"University of Saskatchewan \/ University of Chicago | University of Calgary | University of Alberta | Gabrail Cancer Center Research | Wagner College, Staten Island, NY, USA | `Applied Speciation and Consulting LLC"},{"orgOrder":0,"company":"Affiliated Hospital to Academy of Military Medical Sciences","sponsor":"Ivy Institute of Stem Cells Co. Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Human Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"Affiliated Hospital to Academy of Military Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affiliated Hospital to Academy of Military Medical Sciences \/ Ivy Institute of Stem Cells Co. Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Affiliated Hospital to Academy of Military Medical Sciences \/ Ivy Institute of Stem Cells Co. Ltd"},{"orgOrder":0,"company":"CytoAgents","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"CTO1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"CytoAgents \/ National Institutes of Health"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Quotient Sciences

                            United Kingdom
                            PODD Partnership
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothQuotient Sciences- Molecule to Cure. Fast.

                            Lead Product(s) : GP1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase I/ Phase II

                            Sponsor : CytoAgents

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Quotient Sciences and CytoAgents Accelerate Potential Treatment for COVID-19 Cytokine Storm

                            Details : The collaboration aims to focus on the development of GP1681 (CTO1681), which is a small molecule inhibitor of cytokine release targeting the NF-kB signaling pathway via the activation of the EP4 receptor. It is under development for treatment of cytokin...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 28, 2020

                            Lead Product(s) : GP1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : CytoAgents

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            Quotient

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CytoAgents

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            CytoAgents

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTO1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase I/ Phase II

                            Sponsor : National Institutes of Health

                            Deal Size : $2.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            CytoAgents Receives Fourth Grant From National Institutes of Health

                            Details : The proceeds will accelerate the development of CTO1681, an investigational new drug that uses a novel approach to prevent and mitigate CRS and ICANS.

                            Product Name : CTO1681

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 01, 2025

                            Lead Product(s) : CTO1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : National Institutes of Health

                            Deal Size : $2.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CytoAgents

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            CytoAgents

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTO1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CytoAgents Completes Phase 1B Cohort 1 for Cytokine Release Syndrome

                            Details : CTO1681 is a GPCR agonist, small molecule drug candiate, which is being evaluated for the treatment of cytokine release syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 24, 2025

                            Lead Product(s) : CTO1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CytoAgents

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            CytoAgents

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTO1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CytoAgents Announces Initiation of Patient Enrollment in Phase 1b/2a Clinical Trial to Treat Cytokine Release ...

                            Details : CTO1681 cell therapy, prevents and treats Cytokine Release Syndrome by targeting the NF-kB signaling pathway via the activation of the EP4 receptor, which reduces NF-kB signaling.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 17, 2023

                            Lead Product(s) : CTO1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            CytoAgents

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            CytoAgents

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTO1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy

                            Details : CTO1681 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Cytokine Release Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 15, 2023

                            Lead Product(s) : CTO1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Humanigen

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed

                            Humanigen

                            U.S.A arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lenzilumab

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Humanigen Secures U.S. Patent for Lenzilumab in Preventing Cytokine Storm and Neurotoxicity Related to CAR-T C...

                            Details : The patent covers the use of lenzilumab to prevent or treat cytokine release syndrome (CRS), neurotoxicity and otherwise inhibit or reduce incidence or severity of CAR-T-related toxicities in patients undergoing CAR-T cell therapy.

                            Product Name : Humaneered

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            December 28, 2020

                            Lead Product(s) : Lenzilumab

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Leiden University

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Leiden University

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nivolumab

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TIL and Anti-PD1 in Metastatic Melanoma

                            Details : Nivolumab is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Drug-Related Side Effects and Adverse Reactions.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 20, 2018

                            Lead Product(s) : Nivolumab

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Affiliated Hospital to Academy of Military Medical Sciences

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            Affiliated Hospital to Academy of Military Medical Sciences

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Umbilical Cord Mesenchymal Stem Cell

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Ivy Institute of Stem Cells Co. Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Paraquat Poisoning Induced Lung Injury

                            Details : Human Umbilical Cord Mesenchymal Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Poisoning.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            May 15, 2015

                            Lead Product(s) : Human Umbilical Cord Mesenchymal Stem Cell

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Ivy Institute of Stem Cells Co. Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            University of Saskatchewan

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            University of Saskatchewan

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Anhydrous Selenite

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase I/ Phase II

                            Sponsor : University of Chicago | University of Calgary | University of Alberta | Gabrail Cancer Center Research | Wagner College, Staten Island, NY, USA | `Applied Speciation and Consulting LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Selenium and Arsenic Pharmacodynamics

                            Details : Anhydrous Selenite is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Arsenic Poisoning.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            March 03, 2015

                            Lead Product(s) : Anhydrous Selenite

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : University of Chicago | University of Calgary | University of Alberta | Gabrail Cancer Center Research | Wagner College, Staten Island, NY, USA | `Applied Speciation and Consulting LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            University of Minnesota

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed

                            University of Minnesota

                            Country arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cyclosporine

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase I/ Phase II

                            Sponsor : F. Hoffmann-La Roche | Pfizer Inc | Sanofi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Calcineurin Inhibitor Sparing After Kidney Transplantation

                            Details : Cyclosporine is a Peptide drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Drug-Related Side Effects and Adverse Reactions.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            February 04, 2010

                            Lead Product(s) : Cyclosporine

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : F. Hoffmann-La Roche | Pfizer Inc | Sanofi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth